[go: up one dir, main page]

MA27544A1 - CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES. - Google Patents

CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES.

Info

Publication number
MA27544A1
MA27544A1 MA27686A MA27686A MA27544A1 MA 27544 A1 MA27544 A1 MA 27544A1 MA 27686 A MA27686 A MA 27686A MA 27686 A MA27686 A MA 27686A MA 27544 A1 MA27544 A1 MA 27544A1
Authority
MA
Morocco
Prior art keywords
growth hormone
human growth
chemically modified
modified human
hormone conjugates
Prior art date
Application number
MA27686A
Other languages
French (fr)
Inventor
Rory F Finn
Ned R Siegel
Wei Liao
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MA27544A1 publication Critical patent/MA27544A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Conjugués de l'hormone de croissance humaine chimiquement modifiés La présente invention décrit une hormone de croissance humaine (hGH) modifiée chimiquement par liaison de la protéine avec un polymère soluble dans l'eau. La protéine modifiée au sens de l'invention, présente une activité hGH qui dure beaucoup plus longtemps que celle de l'hormone non modifiée, ce qui permet d'en réduire la dose et la fréquence d'administration.The present invention describes a chemically modified human growth hormone (hGH) by binding of the protein with a water-soluble polymer. The modified protein within the meaning of the invention has an hGH activity which lasts much longer than that of the unmodified hormone, which makes it possible to reduce the dose and the frequency of administration.

MA27686A 2001-11-20 2004-05-19 CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES. MA27544A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33190701P 2001-11-20 2001-11-20

Publications (1)

Publication Number Publication Date
MA27544A1 true MA27544A1 (en) 2005-10-03

Family

ID=23295870

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27686A MA27544A1 (en) 2001-11-20 2004-05-19 CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES.

Country Status (25)

Country Link
EP (1) EP1453859A2 (en)
JP (2) JP2005525302A (en)
KR (2) KR20050044858A (en)
CN (1) CN1608079A (en)
AP (1) AP2004003050A0 (en)
AU (1) AU2002356990A1 (en)
BR (1) BR0214451A (en)
CA (1) CA2467731A1 (en)
CO (1) CO5580794A2 (en)
EA (2) EA008505B1 (en)
EC (1) ECSP045114A (en)
GE (1) GEP20063860B (en)
HR (1) HRP20040448A2 (en)
HU (1) HUP0500997A2 (en)
IL (1) IL162031A0 (en)
IS (1) IS7268A (en)
MA (1) MA27544A1 (en)
MX (1) MXPA04004809A (en)
NO (1) NO20042182L (en)
OA (1) OA13063A (en)
PL (1) PL374354A1 (en)
RS (1) RS53104A (en)
TN (1) TNSN04090A1 (en)
WO (1) WO2003044056A2 (en)
ZA (1) ZA200403907B (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
WO2003049699A2 (en) * 2001-12-11 2003-06-19 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
EA009783B1 (en) * 2002-01-18 2008-04-28 Байоджен Айдек Ма Инк. Polyalkylene glycolhaving a moiety for conjugation of a biologically active compound
GEP20074193B (en) 2002-09-09 2007-09-10 Nektar Therapeutics Al Corp Water-soluble polymer alkanals
EP1591467A1 (en) * 2002-09-09 2005-11-02 Nektar Therapeutics Al, Corporation Conjugate between a polyethylene glycol having a terminal alkanal group and a human growth hormone
US20040142870A1 (en) * 2002-11-20 2004-07-22 Finn Rory F. N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
US20050281778A1 (en) * 2003-03-28 2005-12-22 Myung-Ok Park Human growth hormone conjugated with biocompatible polymer
EP1677819A1 (en) * 2003-10-10 2006-07-12 Novo Nordisk A/S Long-acting molecules in sustained release formulations
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
BRPI0506864A (en) * 2004-01-21 2007-05-29 Novo Nordisk As method for conjugating peptides, conjugated peptide, compound and pharmaceutically acceptable salts, prodrugs and solvates thereof, pharmaceutical composition, use of a compound, and method for treating disease
CN101010105A (en) * 2004-08-31 2007-08-01 法玛西雅厄普约翰有限责任公司 Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
CN104803865A (en) 2004-12-22 2015-07-29 Ambrx公司 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CA2590462C (en) * 2004-12-22 2017-02-28 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
BRPI0519430A2 (en) * 2004-12-22 2009-02-10 Ambrx Inc modified human growth hormone
US20090105134A1 (en) 2005-02-10 2009-04-23 Novo Nordisk A/S C-Terminally Pegylated Growth Hormones
ES2357550T3 (en) 2005-04-18 2011-04-27 Novo Nordisk A/S VARIANTS OF IL-21.
BRPI0615351A2 (en) * 2005-08-30 2011-05-17 Novo Nordisk Healthcare Ag liquid formulations of pegylated growth hormone
CN101400646A (en) * 2005-11-08 2009-04-01 Ambrx公司 Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
EP1968635B1 (en) 2005-12-14 2014-09-17 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US9175061B2 (en) * 2006-07-07 2015-11-03 Novo Nordisk Health Care Ag Protein conjugates and methods for their preparation
CN101108895B (en) * 2006-07-19 2011-10-26 北京键凯科技有限公司 Polyglycol ethanal derivant and combo of medicament and the same
EP2091968A2 (en) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21 variants
CL2008002399A1 (en) * 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
KR101521674B1 (en) * 2008-04-03 2015-05-19 바이오스티드 진 익스프레션 테크. 컴파니 리미티드 Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
KR101104574B1 (en) * 2008-05-14 2012-01-11 성균관대학교산학협력단 Human Growth Hormone Chemically Modified with Polyethylene Glycol, Method of Preparation and Use thereof
EP2313457B1 (en) * 2008-07-31 2020-01-15 PharmaEssentia Corp. Peptide-polymer conjugates
KR20110039348A (en) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Conjugated Proteins with Extended In Vivo Efficacy
RU2409669C9 (en) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Method for immobilising biologically active substance (bas) on carrier (versions) and bas-carrier conjugate produced by such methods
US8492503B2 (en) * 2008-09-11 2013-07-23 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
MX2011007736A (en) 2009-01-22 2011-09-06 Novo Nordisk Healthcare Ag Stable growth hormone compounds.
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
SI2512450T1 (en) 2009-12-15 2018-05-31 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
CN106139158B (en) 2010-01-22 2024-06-21 诺沃—诺迪斯克保健股份有限公司 Growth hormone with prolonged in vivo efficacy
CA2787895A1 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Stable growth hormone compounds
CA2798518A1 (en) * 2010-05-17 2011-11-24 Cebix, Inc. Pegylated c-peptide
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
EA019967B1 (en) * 2011-12-21 2014-07-30 Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт") Polyethyleneglycol covalent conjugate with human growth hormone
EP2981282B1 (en) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
HRP20231732T1 (en) 2014-11-06 2024-03-15 Pharmaessentia Corporation Dosage regimen for pegylated interferon
WO2016079114A1 (en) 2014-11-18 2016-05-26 Ascendis Pharma Growth Disorders Division A/S Novel polymeric hgh prodrugs
EP3988083A1 (en) 2014-11-21 2022-04-27 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
KR20170125839A (en) * 2015-03-11 2017-11-15 넥타르 테라퓨틱스 Conjugates of an il-7 moiety and an polymer
BR112018004208A2 (en) * 2015-09-18 2018-09-25 University Of Miyazaki Prolonged operation type Adreno medullin derivative
CN114539384B (en) * 2020-11-19 2024-09-06 江苏众红生物工程创药研究院有限公司 Pegylated long-acting growth hormone, preparation method and medical application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DE69128944T2 (en) * 1990-05-04 1998-06-25 American Cyanamid Co Stabilization of somatotropin through modification of cysteine residues
CA2101918A1 (en) * 1991-03-18 1992-09-19 Samuel Zalipsky Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
PT1568772E (en) * 1995-09-21 2010-04-14 Genentech Inc Human growth hormone variants
EP1881005B1 (en) * 1997-07-14 2013-04-03 Bolder Biotechnology, Inc. Derivatives of G-CSF and related proteins
JP2002534119A (en) * 1999-01-14 2002-10-15 ボルダー バイオテクノロジー， インコーポレイテッド Method for producing a protein having a free cysteine residue
ATE246202T1 (en) * 1999-01-29 2003-08-15 Hoffmann La Roche GCSF CONJUGATES
AU2001289307A1 (en) * 2000-04-06 2001-10-23 Pharmacia Corporation Chemically-modified myelopoietin conjugates
JP2004524020A (en) * 2001-01-11 2004-08-12 マキシゲン・エイピーエス Improved growth hormone molecule

Also Published As

Publication number Publication date
ECSP045114A (en) 2004-07-23
OA13063A (en) 2006-11-10
JP2005525302A (en) 2005-08-25
AU2002356990A1 (en) 2003-06-10
CO5580794A2 (en) 2005-11-30
MXPA04004809A (en) 2004-08-11
EA200700431A1 (en) 2008-02-28
NO20042182L (en) 2004-08-11
TNSN04090A1 (en) 2006-06-01
ZA200403907B (en) 2007-12-27
PL374354A1 (en) 2005-10-17
GEP20063860B (en) 2006-06-26
KR20070072924A (en) 2007-07-06
HRP20040448A2 (en) 2006-02-28
WO2003044056A3 (en) 2003-08-21
EA200400565A1 (en) 2005-06-30
IS7268A (en) 2004-05-17
KR20050044858A (en) 2005-05-13
BR0214451A (en) 2006-05-30
WO2003044056A2 (en) 2003-05-30
EP1453859A2 (en) 2004-09-08
IL162031A0 (en) 2005-11-20
RS53104A (en) 2006-10-27
JP2006321808A (en) 2006-11-30
EA008505B1 (en) 2007-06-29
CN1608079A (en) 2005-04-20
CA2467731A1 (en) 2003-05-30
AP2004003050A0 (en) 2004-06-30
HUP0500997A2 (en) 2007-11-28

Similar Documents

Publication Publication Date Title
MA27544A1 (en) CHEMICALLY MODIFIED HUMAN GROWTH HORMONE CONJUGATES.
EA200300856A1 (en) LONG-LIVATING DERIVATIVES OF THE GROWTH HORMONE REHEADING FACTOR
WO2004050016A3 (en) Delivery of pharmaceutical agents via the human insulin receptor
WO1998051325A3 (en) Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods
ATE383375T1 (en) WTI-MODIFIED PEPTIDE
EP2275541A3 (en) Method for controlling the activity of immunologically functional molecule
DK1715887T3 (en) N-terminal Monopegylated Human Growth Hormone Conjugates, Methods for their Preparation and Use
BR0212522A (en) Zinc binding ligand, insulin hexamer, aqueous insulin preparation and methods of prolonging the action of an insulin preparation and preparing a zinc binding ligand
ATE551362T1 (en) PEPTIDES THAT LOWER BLOOD SUGAR CONTENT
ATE68976T1 (en) SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS.
ATE107514T1 (en) STABILIZED PROTEIN OR PEPTIDE CONJUGATES.
EA199900979A1 (en) COMPOSITIONS OF ACTIVATED PROTEIN
DK1212422T3 (en) Human CTLA-4 antibodies and their uses
CY1108765T1 (en) ANTI-ErbB2 antibody treatment
EE200100507A (en) Hydroxymatairesinol for cancer prevention
BR0316716A (en) Chemically Modified Human Growth Hormone Conjugates
PT1146896E (en) FORMULATIONS MONODISPERSAS OF ANILOGO ACILADO AND HEXAMERICO INSULINA
EA200100905A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PROTONE PUMP INHIBITORS
EP1071443A4 (en) ISOLATED PEPTIDES CORRESPONDING TO NY-ESO-1 AMINO ACID SEQUENCES THAT BIND TO CLASS I MHC AND CLASS II MHC MOLECULES, AND USES THEREOF
NO20054440L (en) Liquid formulations of tumor necrosis factor binding proteins
WO2000006185A3 (en) Methods of using lanreotide, a somatostatin analogue
FR2821359B1 (en) HETEROCARPINE, A PROTEIN FIXING HUMAN GHRH
EA200600331A1 (en) APPLICATION OF HUMAN HORMONE OF GROWTH IN MULTIPLE SYSTEMIC ATROPHY
CY1108761T1 (en) DISABILIZED CATS FOR IMMUNIZATION
ATE263247T1 (en) PEPTIDE FROM HUMAN INTERLEUKIN-2 TO INCREASE VASOPERMEABILITY AND ITS IMMUNE CONJUGATES